JP Morgan Chase
RGNX icon

JP Morgan Chase’s Regenxbio RGNX Stock Holding History

JP Morgan Chase’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$27.1M Sell
3,483,800
-69,702
-2% -$732K ﹤0.01% 1832
2025
Q4 		$51.2M Sell
3,553,502
-483,746
-12% -$6.03M ﹤0.01% 1350
2025
Q3 		$39M Buy
4,037,248
+185,223
+5% +$1.64M ﹤0.01% 1575
2025
Q2 		$31.6M Sell
3,852,025
-512,318
-12% -$4.29M ﹤0.01% 1624
2025
Q1 		$31.2M Buy
4,364,343
+227,826
+6% +$1.69M ﹤0.01% 1578
2024
Q4 		$32M Buy
4,136,517
+1,659,206
+67% +$15.6M ﹤0.01% 1620
2024
Q3 		$26M Sell
2,477,311
-535,165
-18% -$6.52M ﹤0.01% 1776
2024
Q2 		$35.2M Sell
3,012,476
-710,077
-19% -$11.1M ﹤0.01% 1448
2024
Q1 		$78.4M Sell
3,722,553
-216,996
-6% -$3.86M 0.01% 1056
2023
Q4 		$70.7M Buy
3,939,549
+274,185
+7% +$4.83M 0.01% 1056
2023
Q3 		$60.3M Sell
3,665,364
-36,215
-1% -$656K 0.01% 1024
2023
Q2 		$74M Sell
3,701,579
-304,044
-8% -$5.86M 0.01% 963
2023
Q1 		$75.7M Buy
4,005,623
+211,146
+6% +$4.67M 0.01% 909
2022
Q4 		$86.1M Sell
3,794,477
-260,178
-6% -$5.88M 0.01% 840
2022
Q3 		$107M Sell
4,054,655
-190,241
-4% -$5.64M 0.02% 702
2022
Q2 		$105M Sell
4,244,896
-479,797
-10% -$12M 0.01% 732
2022
Q1 		$157M Sell
4,724,693
-280,080
-6% -$7.78M 0.02% 646
2021
Q4 		$164M Buy
5,004,773
+864,447
+21% +$29.4M 0.02% 655
2021
Q3 		$174M Buy
4,140,326
+418,481
+11% +$15.1M 0.02% 620
2021
Q2 		$145M Buy
3,721,845
+220,966
+6% +$7.9M 0.02% 733
2021
Q1 		$119M Buy
3,500,879
+899,513
+35% +$38.4M 0.02% 768
2020
Q4 		$118M Buy
2,601,366
+615,254
+31% +$21.5M 0.02% 719
2020
Q3 		$55.4M Buy
1,986,112
+70,551
+4% +$2.3M 0.01% 926
2020
Q2 		$70.5M Buy
1,915,561
+412,215
+27% +$15.4M 0.01% 764
2020
Q1 		$48.7M Buy
1,503,346
+132,212
+10% +$5.51M 0.01% 806
2019
Q4 		$56.2M Buy
1,371,134
+138,595
+11% +$5.47M 0.01% 903
2019
Q3 		$43.9M Buy
1,232,539
+50,405
+4% +$2.04M 0.01% 1017
2019
Q2 		$58.8M Sell
1,182,134
-23,311
-2% -$1.16M 0.01% 889
2019
Q1 		$69.1M Buy
1,205,445
+109,620
+10% +$5.43M 0.01% 808
2018
Q4 		$46M Buy
1,095,825
+27,877
+3% +$1.64M 0.01% 937
2018
Q3 		$80.6M Sell
1,067,948
-14,058
-1% -$1.01M 0.02% 796
2018
Q2 		$77.6M Sell
1,082,006
-397,094
-27% -$19M 0.02% 750
2018
Q1 		$44.2M Sell
1,479,100
-37,808
-2% -$1.1M 0.01% 1008
2017
Q4 		$50.4M Buy
1,516,908
+246,581
+19% +$7.43M 0.01% 977
2017
Q3 		$40.8M Buy
1,270,327
+43,492
+4% +$979K 0.01% 1053
2017
Q2 		$24.2M Buy
1,226,835
+51,041
+4% +$988K 0.01% 1327
2017
Q1 		$22.7M Buy
1,175,794
+176,047
+18% +$3.4M 0.01% 1391
2016
Q4 		$18.5M Sell
999,747
-12,919
-1% -$247K ﹤0.01% 1509
2016
Q3 		$14.2M Buy
1,012,666
+690,084
+214% +$7.62M ﹤0.01% 1570
2016
Q2 		$2.58M Sell
322,582
-8,758
-3% -$97.2K ﹤0.01% 2677
2016
Q1 		$3.58M Sell
331,340
-27,412
-8% -$351K ﹤0.01% 2392
2015
Q4 		$5.96M Buy
358,752
+140,278
+64% +$2.78M ﹤0.01% 2109
2015
Q3 		$4.81M Buy
+218,474
New +$5.58M ﹤0.01% 2251

Other funds holding RGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

JP Morgan Chase's RGNX Position: Q1 2026 in Review

JP Morgan Chase reduced its Regenxbio (RGNX) stake by 2% in Q1 2026, selling an estimated $732K and leaving 3,483,800 shares worth $27.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1832.

JP Morgan Chase first reported a position in RGNX in Q3 2015 and has held it in 43 quarters since. The position peaked at $174M in Q3 2021. 178 funds tracked by Wall St. Rank hold RGNX as of Q1 2026.

  • JP Morgan Chase held 3,483,800 shares of Regenxbio worth $27.1M as of Q1 2026.
  • JP Morgan Chase sold 69,702 Regenxbio shares in Q1 2026, an estimated $732K.
  • Regenxbio made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #1832 holding.
  • JP Morgan Chase first reported a position in Regenxbio in Q3 2015 and has held it in 43 quarters since.
  • JP Morgan Chase's Regenxbio position peaked at $174M in Q3 2021.
  • 178 funds tracked by Wall St. Rank held Regenxbio as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.